Cormedix Inc (CRMD)
$5.42
Insights on Cormedix Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 6.81K → 29.70K (in $), with an average increase of 77.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -9.74M → -14.75M (in $), with an average decrease of 51.4% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 32.4%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 275.5%
Performance
- $5.33$5.74$5.42
1.66%
Downside
Day's Volatility :7.09%
Upside
5.52%
- $2.57$7.00$5.42
52.58%
Downside
52 Weeks Volatility :63.29%
Upside
22.57%
Returns
| Period | Cormedix Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 65.85% | -0.7% | 0.0% |
6 Months | 65.85% | 6.6% | 0.0% |
1 Year | 14.29% | 3.7% | -1.5% |
3 Years | -27.85% | 14.0% | -21.8% |
Highlights
Market Capitalization | 297.4M |
Book Value | $1.28 |
Earnings Per Share (EPS) | -0.91 |
PEG Ratio | 0.0 |
Wall Street Target Price | 13.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -42.47% |
Return On Equity TTM | -74.02% |
Revenue TTM | 29.7K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -47.3% |
Gross Profit TTM | 61.7K |
EBITDA | -48.9M |
Diluted Eps TTM | -0.91 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.74 |
EPS Estimate Next Year | -0.09 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.26 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 139.85%
Technicals Summary
Sell
Neutral
Buy
Cormedix Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Cormedix Inc | 43.16% | 65.85% | 14.29% | -27.85% | -34.38% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Cormedix Inc | NA | NA | 0.0 | -0.74 | -0.74 | -0.42 | NA | 1.28 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Cormedix Inc | Buy | $297.4M | -34.38% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
BlackRock Inc
6.38%Nomura Holdings Inc
5.36%Vanguard Group Inc
5.14%Elliott Investment Management L.P.
2.82%Geode Capital Management, LLC
2.11%State Street Corporation
1.95%
Corporate Announcements
Cormedix Inc Earnings
Cormedix Inc’s price-to-earnings ratio stands at None
Read More
Company Information
cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.
Organization | Cormedix Inc |
Employees | 82 |
CEO | Mr. Joseph Todisco MBA |
Industry | Health Technology |
